Previous Close | 5.99 |
Open | 5.99 |
Bid | 6.31 x 1300 |
Ask | 6.36 x 900 |
Day's Range | 5.90 - 6.37 |
52 Week Range | 3.42 - 9.74 |
Volume | 71,088 |
Avg. Volume | 109,160 |
Market Cap | 134M |
Beta (3Y Monthly) | 2.91 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.75 |
Earnings Date | Nov 6, 2019 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 30.70 |
Top Ranked Momentum Stocks to Buy for December 4th
NASH sees a highly rewarding market with candidates of blockbuster potential. Let us take a look at the hits and misses in this space so far this year.
Q3 2019 Galmed Pharmaceuticals Ltd Earnings Call
- Conference Call and Webcast Today at 8:30 a.m. EST / 5:30 a.m. PST - TEL AVIV, Israel , Nov. 6, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), ...
This week we saw the Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) share price climb by 22%. But that isn't much...
TEL AVIV, Israel, Oct. 31, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in Phase 3/4 clinical trial for the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis announced today that it will present new data at The Liver Meeting®, the annual meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, November 8-12, 2019. This new pre-clinical data elucidates the mechanism by which Aramchol affects glucose metabolism in the liver that resulted in a reduction of HbA1C in patients in the Company's Phase IIb trial. The data suggests that Aramchol improves liver glucose homeostasis in patients and murine models.
TEL AVIV, Israel , Oct. 30, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development ...
TEL AVIV, Israel, Sept. 26, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol, an oral therapy for the treatment of nonalcoholic steatohepatitis ("NASH") and fibrosis, announced today the initiation of its Phase 3/4 ARMOR clinical study to evaluate the efficacy and safety of Aramchol in subjects with NASH and fibrosis. This double-blind, placebo-controlled, global study will be conducted in approximately 185 sites in the U.S., Europe, Latin America and Asia. The ARMOR study will evaluate the efficacy and safety of Aramchol in subjects with NASH and fibrosis stages 2-3 who are overweight or obese and have prediabetes or type 2 diabetes. A total of 2000 subjects will be randomized 2:1 to receive Aramchol 300mg BID or matching placebo.
Trailing twelve-month data shows us that Galmed Pharmaceuticals Ltd.'s (NASDAQ:GLMD) earnings loss has accumulated to...
Q2 2019 Galmed Pharmaceuticals Ltd Earnings Call
- Conference Call and Webcast Today at 8:30 a.m. EST / 5:30 a.m. PST - TEL AVIV, Israel , Aug. 5, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), ...
TEL AVIV, Israel , July 29, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development ...
Every investor in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) should be aware of the most powerful shareholder groups...
In 2012 Allen Baharaff was appointed CEO of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD). This report will, first...
Galmed Pharmaceuticals (GLMD) delivered earnings and revenue surprises of 10.53% and -100.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Tel Aviv, Israel-based company said it had a loss of 17 cents. The results beat Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research ...
Conference Call and Webcast Today at 8:30 a.m. EST / 5:30 a.m. PST TEL AVIV, Israel , May 7, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), ...
TEL AVIV, Israel , April 30, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development ...
TEL AVIV, Israel, April 9, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator, Aramchol, an oral therapy for the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis, announced today that the company has completed its End-of-Phase 2 meeting with the Food and Drug Administration (FDA) and reached general agreement on key aspects of the Phase 3/4 development and registration plan for Aramchol and on the pivotal registration study ARMOR. ARMOR is a Phase 3/4 multinational, multicenter, double-blind, placebo-controlled clinical study to evaluate the efficacy, safety and tolerability of Aramchol in subjects with NASH and fibrosis.
Galmed Pharmaceuticals (GLMD) delivered earnings and revenue surprises of -58.33% and -100.00%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
- Conference Call and Webcast Today at 8:30 a.m. EST / 5:30 a.m. PST - TEL AVIV, Israel , March 13, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), ...
It hasn't been the best quarter for Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) shareholders, since the share price has fallen 17% in that time. But that doesn't change the fact that theRead More...
The aim of this Phase I, open-label, two-period, randomized, crossover PK study was to assess whether dose splitting of Aramchol 600mg to twice daily 300mg will significantly increase plasma levels. 16 healthy subjects took part in two study periods.
TEL AVIV, Israel , March 6, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmedˮ or the "Company"), a clinical-stage biopharmaceutical company focused on the development ...
Intercept (ICPT) outperforms the broader market in 2018 as lead drug Ocaliva recovers, following the company's efforts to increase awareness about the updated label.